Medical Crossfire®: How the Experts Identify and Target EGFR exon 20 Insertion Mutations Across Lines of Care in NSCLC

Approximately 10% to 20% of lung cancer cases in the United States are EGFR mutation–positive. Of these EGFR mutation–positive patients, a significant subset will have EGFR mutations that do not respond to clinically available EGFR tyrosine kinase inhibitors (TKIs), in particular, EGFR exon 20 insertion mutations.

The Medical Crossfire^™, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 3 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC). This lively discussion will help place new developments into clinical context to help you optimize care for your patients with NSCLC.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Oncology.
 

Instructions for This Activity and Receiving Credit Complete the activity (including pre- and post-activity assessments). Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate.

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine the role of EGFR exon 20 insertion mutations in tumor biology and outcomes for patients with advanced NSCLC
• Apply optimal molecular testing strategies for patients with NSCLC and EGFR exon 20 insertions along care continuum
• Evaluate safety and efficacy results from clinical trials that assessed novel approaches for the management of patients with advanced NSCLC and EGFR exon 20 insertions
• Contextualize recent evidence on EGFR exon 20 insertion-directed systemic therapies and their potential impact on treatment paradigms for patients with advanced forms of NSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.
 

Chair

Disclosures:Consultant: Abbvie, Accutar Biotechnology, ACEA Biosciences, Allorion Therapeutics, Araxes Pharma, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo, Eli Lilly and Co, Esai, Ignyta, Loxo Oncology, Mirati Therapeutics, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta, Voronoi Inc; Stock Ownership: Gatekeeper Pharmaceuticals; Research Funding: Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and Co, Puma Biotechnology, Revolution Medicines, Takeda Oncology; Patents, Royalties, Other: LabCorp.

Faculty

Disclosures: Mary Beth Beasley, MD, has no relevant financial relationships with ineligible companies.

Disclosures: Grant/Research Support: Eli Lilly and Co, Mirati Therapeutics, Novartis, Pfizer, Roche, Takeda Oncology.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.